The CDC recommends that pregnant women including with HIV-infection and confirmed, probable, or suspected 
influenza A (H1N1) are at risk of potentially serious disease due to influenza viruses and need to receive antiviral therapy with Oseltamivir (Tamiflu).
Although the safety and efficacy of oseltamivir of oseltamivir during pregnancy have not been firmly established, the benefits of this antiviral drug are likely to outweigh the risks. Oseltamivir therapy should be initiated as soon as possible, even if more than 48 hours have elapsed since symptom onset. If pregnant women had a close contact with a confirmed, probable, or suspected novel H1N1 infection, they should receive with either oseltamivir or zanamivir for 10 days.
Pregnancy should not be considered as a contraindication to the use of oseltamivir or zanamivir, according to an article describe consideration for clinicians regarding pregnant women and influenza A (H1N1) infection. It is stated that since both antiviral medication has the unknown effect on pregnant women and their fetus, oseltamivir or zanamivir should be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus. And oseltamivir is preferred because of its systemic activity.
